See the DrugPatentWatch profile for tafinlar
When does Tafinlar’s patent exclusivity end?
The exact date depends on which form of “exclusivity” you mean—patent term, regulatory exclusivity granted by the FDA, or exclusivity in a specific country. The information provided here does not include Tafinlar’s patent or exclusivity expiry dates, so a definitive timeline can’t be stated.
What counts as “exclusivity” for a cancer drug like Tafinlar?
People often mean one of these:
- Patent term ending for the drug substance or specific formulations/methods.
- FDA-granted exclusivity periods (which are separate from patents).
- Data exclusivity and related protections that can delay approvals of competing products.
Without the relevant patent/exclusivity records or a jurisdiction, the end date can’t be determined.
How to find the actual expiry date (fast and reliably)
To get the correct loss-of-exclusivity date, check:
- FDA Orange Book listings for Tafinlar (to see listed patents and patent expiration dates by active ingredient and product).
- The FDA exclusivity information for the Tafinlar NDA (to see regulatory exclusivity start/end dates, if applicable).
- The specific country’s IP/regulatory system if the question is outside the US.
If you tell me the country, I can narrow it down
Patent and regulatory exclusivity timelines differ by jurisdiction. If you confirm:
1) Tafinlar in the US (FDA) or another country (which one), and
2) whether you mean patent expiry or FDA regulatory exclusivity,
I can point you to the specific expiry date from the right source format (Orange Book vs exclusivity listing).
Sources: None (the provided content does not include patent/exclusivity expiry data for Tafinlar).